Jeremy Johnson, PharmD, on how oral and injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are helping high-risk patients hit LDL targets statins alone can't reach.
Jeremy L. Johnson, PharmD, BCACP, CDCES, BC-ADM
Advertisement
Jeremy L. Johnson, PharmD, BCACP, CDCES, BC-ADM, is professor of pharmacy practice at the Southwestern Oklahoma State University College of Pharmacy.
Articles by Jeremy L. Johnson, PharmD, BCACP, CDCES, BC-ADM
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Phase 3 Trial Marks First Success for Personalized mRNA Cancer Therapy in Resected Melanoma
2
FDA Approves Garetosmab-grts, First Treatment for FOP Bone Growth
3
Fentanyl-Responsive Microneedle Patch Automatically Releases Naloxone in Preclinical Study
4
Delegating to Technicians: The Key to Pharmacists Practicing at Top of License
5